Canaccord Genuity Raises Price Target Following Intuitive Surgical's (ISRG) 3Q15 Earnings Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pre-Open Stock Movers 10/21: (KLAC) (ISRG) (SNDK) Higher; (SNTA) (VMW) (TWTR) Lower (more...)
October 21, 2015 9:27 AM EDTSynta Pharmaceuticals Corp. (NASDAQ: SNTA) 66.7% LOWER; announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the studys Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint... More
Intuitive Surgical (ISRG) 'Outperform' Reiterated, PT Trimmed to $593 at Leerink Partners
October 21, 2015 9:00 AM EDTLeerink Partners analyst Richard Newitter reiterated an Outperform rating on Intuitive Surgical (NASDAQ: ISRG) following solid Q3 results but trimmed his price target to $593.00 (from $600.00).
Newitter commented, "ISRG's 3Q saw above-expectations system rev, procedure growth, and GM. The outperformance (plus upped procedure & GM... More
Intuitive Surgical (ISRG) PT Lifted to $565 at Evercore ISI Amid Strong Q3
October 21, 2015 8:11 AM EDTEvercore ISI analyst Vijay Kumar reiterated a Buy rating and raised his price target on Intuitive Surgical (NASDAQ: ISRG) to $565.00 (from $545.00) following strong Q3 results.
Kumar commented, "3Q was a déjà vu of 2Q, highlighted by a STRONG procedure growth and decent systems placements, with the caveat being an even more impressive margin pull through. This was one of the most complete quarters that ISRG has put up... More
After-Hours Movers 10/20: (ISRG) (MANH) (CREE) Higher; (CMG) (IRBT) (VMW) (YHOO) Lower (more...)
October 20, 2015 5:59 PM EDTIntuitive Surgical (NASDAQ: ISRG) 7.6% HIGHER; reported Q3 EPS of $5.24, $1.01 better than the analyst estimate of $4.23. Revenue for the quarter came in at $590 million versus the consensus estimate of $580.37 million.
Chipotle Mexican Grill (NYSE: CMG) 7.2% LOWER; reported Q3 EPS of $4.59, $0.04 worse than the analyst estimate of $4.63. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.22 billion.
iRobot Corporation (NASDAQ: IRBT) 5.5% LOWER; reported... More
Intuitive Surgical (ISRG) Tops Q3 EPS by 101c
October 20, 2015 4:09 PM EDTIntuitive Surgical (NASDAQ: ISRG) reported Q3 EPS of $5.24, $1.01 better than the analyst estimate of $4.23. Revenue for the quarter came in at $590 million versus the consensus estimate of $580.37 million.
Worldwide da Vinci procedures grew approximately 15% over the third quarter of 2014, driven... MoreWall Street ends down with healthcare, IBM; United Tech rises
October 20, 2015 7:13 AM EDTBy Caroline Valetkevitch
(Reuters) - U.S. stocks ended slightly lower on Tuesday as a decline in healthcare and biotech stocks offset gains in United Technologies and Verizon.
A 5.7 percent drop to $140.64 in IBM (NYSE: IBM) also weighed on the market. The stock hit a five-year intraday low at $140.28 after it reported a bigger-than-expected decline in quarterly revenue and cut its full-year profit forecast.
The S&P healthcare sector fell 1.5 percent, while the Nasdaq Biotech Index dropped 3.2 percent. Concerns about drug pricing have hit biotech and other healthcare shares.
... More